Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants

Pediatric Infectious Disease Journal

Volumn 17, Issue 7, 1998, Pages 587-593

  O'Shea, T Michael ^a   Sevick, Mary Ann ^a   Givner, Laurence B ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Bronchopulmonary dysplasia; Economic analysis; Immunoglobulin; Prophylaxis; Respiratory syncytial virus

Indexed keywords

RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ACTIVE IMMUNIZATION; ARTICLE; COST BENEFIT ANALYSIS; DRUG EFFICACY; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; INFANT; INFECTION PREVENTION; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS PNEUMONIA;

COST-BENEFIT ANALYSIS; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY TRACT INFECTIONS; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 0031850264     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199807000-00003     Document Type: Article

References (14)

1. Glezen WP, Loda FA, Clyde WA, et al. Epidemiologic patterns of acute lower respiratory disease of children in a pediatric group practice. J Pediatr 1971;78:397-406.
2. Henderson FW, Clyde WA, Collier AM, et al. The etiologic and epidemiologic spectrum of bronchiolitis in pediatric practice. J Pediatr 1979;95:183-90.
3. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988;82:199-203.
4. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial virus infection in infants with congenital heart disease. N Engl J Med 1982;307:397-400.
5. Navas L, Wang E, de Carvalho V, Robinson J, and the Pediatric Investigators Collaborative Network on Infections in Canada. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. J Pediatr 1992;121:348-54.
6. Groothuis JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high risk infants and young children. N Engl J Med 1993;329:1524-30.
7. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997;99:93-9.
8. Simoes EAF, Groothuis JR, Tristram DA, et al. Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high-risk children. J Pediatr 1996;129:214-9.
9. Lubchenco LO, Hansman C, Boyd E. Intrauterine growth as estimated from liveborn birth-weight data at 24 to 42 weeks of gestation. Pediatrics 1963;37:403-8.
10. Avery GB, Fletcher MA, MacDonald MG, eds. Neonatology: pathophysiology and management of the newborn. 4th ed. Philadelphia: Lippincott, 1994:1418.
11. US Department of Labor Bureau of Labor Statistics. CPI detailed report for September, 1996.
12. Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation. Pediatrics 1991;88:527-32.
13. Hay JW, Ernst RL, Meissner HC. Respiratory syncytial virus immune globulin: a cost-effectiveness analysis. Am J Managed Care 1996;2:851-61.
14. Wang EEL, Law BJ, Boucher FD, et al. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1996;129:390-5.